Introduction. Breast cancer is the most common malignancy in women and a leading cause of cancer mortality. The HR-positive/HER2-negative subtype accounts for most cases and is characterized by initial endocrine sensitivity followed by resistance. This study aimed to map and interpret randomized clinical trial evidence on the efficacy and safe...

By Sanja Stojanović Gagović, Nikolina Dukić, Jelena Vladičić Mašić, Dragana Stupar, Nemanja Kovač, Snežana Zečević

Introduction. The development of information technologies in education has enabled the introduction of new teaching approaches, among which the Flipped classroom (FC) model has gained increasing attention. The FC model has emerged as a student-centered approach that promotes active learning in medical education. The aim of this study was to ex...

By Dragan Spaić, Srđan Mašić, Dejan Bokonjić, Nina Rajović, Zoran Bukumirić, Nada Avram, Vladimir Milutinović, Jelena Vladičić Mašić, Jovan Kulić, Radenko Čančar, Nataša Milić

There is a daily increase in the number of patients with malignant diseases, but with the advances in modern oncology research, the number of survivors treated with malignant diseases is becoming larger and larger. The survival rate after completing oncology therapy is increasing on a daily basis, so that malignant diseases belonging to the categor...

By Srđan Popović, Sladjana Popović, Nikolina Dukić, Olivera Čančar, Jelena Vladičić Mašić

The human epidermal growth receptor 2 (HER2, c-erb-B2) is present in 15-20% of breast cancer at the time of diagnosis. Overexpression of HER2 receptor is associated with more aggressive form of breast cancer. Trastuzumab is a human monoclonal antibody that blocks the signaling pathways of cell proliferation by binding to the HER2 receptor. Due to t...

By Dragana Jokanović, Slađana Popović, Olivera Čančar, Nikolina Dukić, Zdenka Gojković, Nenad Lalović, Jelena Vladičić Mašić, Srdjan Mašić